Due to the immunogenicity of NY-ESO-1, it was used as a target in vaccination trials, studies with adoptive T-cell transfer and in combination with immunotherapy to boost immune response against the NY-ESO-1 expressing cancer cells (Thomas et al. 2018). This evidence concerns the gene CTAG1B and cancer.